Tumor Infiltrating Lymphocytes clinical trials
Tumor Infiltrating Lymphocytes is named as an intervention in 10 current clinical trials in our China register. 10 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Essen Biotech (5). The most-studied condition is Breast Cancer.
Patient leaflets for Tumor Infiltrating Lymphocytes
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Tumor Infiltrating Lymphocytes
10 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Tumor Infiltrating Lymphocytes
26 conditionsAll 26 conditions
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 2 |
| Glioma | 2 |
| Treatment Side Effects | 2 |
| Effects of Immunotherapy | 2 |
| Breast Carcinoma | 1 |
| Breast Cancer Metastatic | 1 |
| Breast Cancer Triple Negative | 1 |
| Gastrointestinal Tumor | 1 |
| Stomach Cancer | 1 |
| Stomach Cancer Recurrent | 1 |
| Stomach Cancer, Adenocarcinoma | 1 |
| Esophageal Cancer | 1 |
| Colorectal Cancer | 1 |
| Colon Cancer | 1 |
| Rectum Cancer | 1 |
| Advanced Breast Cancer | 1 |
| Brain Tumor | 1 |
| Brain Metastases | 1 |
| Brain Cancer | 1 |
| Advanced Solid Tumors | 1 |
| Advanced Solid Tumor | 1 |
| Tumor Infiltrating Lymphocytes | 1 |
| Lung Cancer | 1 |
| Lung Cancer Metastatic | 1 |
| Lung Cancer, Non-small Cell | 1 |
| Lung Cancer Recurrent | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Essen Biotech | 5 |
| Shanghai Juncell Therapeutics | 5 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 10 | 10 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Tumor Infiltrating Lymphocytes trials
How many clinical trials are testing Tumor Infiltrating Lymphocytes?
10 current trials in our China register name Tumor Infiltrating Lymphocytes as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.
Are Tumor Infiltrating Lymphocytes trials recruiting patients?
Yes. 10 of the 10 trials are recruiting: 10 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Tumor Infiltrating Lymphocytes clinical trials?
Essen Biotech (5) and Shanghai Juncell Therapeutics (5). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tumor Infiltrating Lymphocytes works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tumor Infiltrating Lymphocytes works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tumor Infiltrating Lymphocytes (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.